Clinical trials on Percutaneous Coronary Intervention (PCI)

Percutaneous Coronary Intervention (PCI): An Overview

Percutaneous Coronary Intervention (PCI), commonly known as coronary angioplasty, is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary artery disease. These narrowed arteries are typically the result of a buildup of atherosclerotic plaques. The primary goal of PCI is to enhance blood flow to the heart muscle, thereby reducing symptoms such as chest pain (angina), improving the quality of life, and, in some cases, extending survival.

The procedure involves the insertion of a catheter (a thin flexible tube) into the narrowed part of the artery. A specialized balloon attached to the catheter is then inflated at the site of the blockage, helping to widen the artery and restore arterial blood flow at an optimal level. In most cases, a stent (a small wire mesh tube) is also deployed to keep the artery open. With advancements in medical technology, the materials and techniques used in PCI have significantly evolved, leading to the development of drug-eluting stents that release medication to help prevent the artery from getting blocked again.

  • Minimally Invasive: Compared to coronary artery bypass grafting (CABG), PCI is less invasive, involves a shorter recovery period, and patients can often return to their normal activities shortly after the procedure.
  • Widely Accessible: PCI has become the most common method of coronary revascularization worldwide, thanks to its effectiveness in quickly relieving symptoms of heart disease.
  • Continuous Innovation: Ongoing research and technological advancements continue to improve the outcomes and safety of PCI, making it a continually evolving field within cardiovascular medicine.

In conclusion, Percutaneous Coronary Intervention (PCI) represents a cornerstone in the management of coronary artery disease, offering a lifesaving option for many patients with minimal downtime and improving overall quality of life.

  • CT-EU-00038623

    Study on single drug therapy in heart patients after stent implantation

    This study is for patients with a heart condition called atrial fibrillation who will be getting a type of heart stent, or tiny tube put into a blood vessel, called a Supraflex Stent. After stenting, patients usually have to take many medications to prevent blood clots. However, these medications can also make people bleed more easily, which is not good. The usual strategy is to give patients three of these medications for a week up to a month, then two for up to 6–12 months, and then just one for the long term. In this study, the investigators will try out a different strategy where only one medication is used at a time. For the first month after stenting, an antiplatelet, a medication to stop blood clotting will be given, then after, an anticoagulant, another type of medication to prevent blood clots will be used. The aim is to see if this approach leads to fewer bleeding problems, while still protecting against blood clots.

    • P2Y12 inhibitor
    • Aspirin
    • DOAC-Direct oral anticoagulant